Bristol-myers Squibb Compnay

Cytomx Therapeutics, Inc.

The Rockefeller University

Bryan C Barnhart

Aaron Paul Yamniuk

Guodong Chen

Richard Y Huang

Alan J Korman

Mohan Srinivasan

Nils Lonberg

Karla Ann Henning

Ming Lei

Liang Schweizer

Sandra V Hatcher

Haichun Huang

Maria N Jure-Kunkel

Brigitte Devaux

Brenda L Stevens

Martin J Corbett

John S Sack

Shannon Lee Okada

Emanuela Sega

Angela Goodenough

Joseph E Myers, Jr

Pingping Zhang

Mark J Selby

James William West

Dasa Lipovsek

Arvind Rajpal

Ginger Chao Rakestraw

Stanley Richard Krystek, Jr

Jeffrey V Ravetch

Kent B Thudium

Han Chang

Changyu Wang

Mark F Maurer

Xi-Tao Wang

Michelle Minhua Han

Irvith M Carvajal

Steven R O'Neil

John Thomas Loffredo

Indrani Chakraborty

Jochem Gokemeijer

Christina Terragni

Huiming Li

Alexander T Kozhich

Thomas D Kempe

Michael Quigley

Susan Chien-Szu Wong

Xiang Shao

Hadia Lemar

Joseph Toth

Rony Dahan

Zhehong Cai

Marie-Michelle Navarro Garcia

Christina Maria Milburn

Patrick Guirnalda

Zheng Yang

Christine Huang

Yan Feng

Praveen Aanur

Joseph E Myers

Stanley Richard Krystek

Maria Rodriguez

Steven R O'NEIL

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Anti-CD40 antibodies and uses thereof

Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that bind to glypican-3. Also provided are fusion molecules comprising aFn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3Fn3 drug conjugates are also provided.

Glypican-3-binding fibronectin based scaffold molecules

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist in combination with a DR4 or DR5 agonist.

Combination of DR5 agonist and anti-PD-1 antagonist and methods of use

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Nucleic acids encoding an anti-CD40 antibody

Provided herein are heavy chain constant regions (referred to as 'modified heavy chain constant regions'), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

Antibodies comprising modified heavy constant regions

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Antibodies to CD40 with enhanced agonist activity

Antibodies against CD73

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Growing community of inventors

San Francisco, CA, United States of America

Bryan C Barnhart